JUPITER Subgroup Analysis Provides Convincing Evidence for Statin Therapy as Primary Prevention for CV Events in Older Individuals

Summary

Results of a subgroup analysis from the JUPITER trial [NCT00239681] showed a significant reduction in major cardiovascular (CV) events in older, apparently healthy individuals who were treated with rosuvastatin compared with placebo.

  • Lipid Disorders
  • Prevention & Screening Clinical Trials
View Full Text